<?xml version='1.0' encoding='utf-8'?>
<document id="31020076"><sentence text="Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series." /><sentence text="The use of direct oral anticoagulants (DOACs) is on the rise in the general population" /><sentence text=" However, data related to the safety of DOACs in patients with malignancy are limited" /><sentence text=" In this brief report, we present a series of three cases of haemorrhagic pericardial effusions and tamponade in patients receiving DOACs while undergoing cancer therapy" /><sentence text=" These three cases were all observed within a period of 6â€‰weeks at a single institution and occurred shortly after the initiation of anticoagulation with one of the DOACs" /><sentence text=" Two of these patients had evidence of neoplastic pericardial process and were being treated with immunotherapy" /><sentence text=" The third patient was receiving targeted cancer therapy with a drug known to be associated with increased bleeding risks" /><sentence text=" Haemorrhagic pericarditis may represent a unique type of DOACs-related complications in subgroups of cancer patients with neoplastic pericardial disease and/or complex pharmacodynamics drug-drug interaction" /><sentence text=" The purpose of this report is to raise awareness of the lack of conclusive safety data of DOACs in certain cancer patients and to remind clinical providers of the National Comprehensive Cancer Network guidelines recommending against their use in patients with malignancy on the basis of limited safety data in patients undergoing cancer therapies" /><sentence text="" /></document>